Content » Vol 42, Issue 7

Original report

Efficacy of botulinum toxin type A treatment of functional impairment of degenerative hip joint: Preliminary results

Corrado Marchini , Michele Acler, M.A. Bolognari, A. Causero, D. Volpe , Dario Regis, Alessandra Rizzo , R. Rosa, R. Eleopra, Paolo Manganotti
DOI: 10.2340/16501977-0546


Objective: The aim of this study was to investigate the effect of botulinum toxin type A injection into the adductor muscles in reducing pain and improving joint mobility and quality of life in patients affected by hip osteoarthritis.
Methods: A total of 39 outpatients, mean age 68 years (age range 41–82 years), were evaluated using the Harris Hip Score to test hip function, a visual analogue scale to measure pain intensity and the Short Form 36 (SF-36) questionnaire to assess patient well-being and quality of life at baseline, 2, 4 and 12 weeks after treatment with botulinum toxin type A. A total of 400 U of botulinum toxin type A (Dysport) was injected into the adductor longus muscle and the adductor magnus muscle.
Results: The Harris Hip Score increased significantly after 2, 4 and 12 weeks (df 3, χ2 = 45.1; p < 0.0001). A significant decrease in pain intensity was detected at all the follow-up visits, after 2, 4 and 12 weeks (df 3; χ2 = 27.8; p < 0.001). The SF-36 score was significantly higher 4 and 12 weeks after treatment. At each evaluation visit a significant correlation was detected between decreased pain and improved hip mobility.
Conclusion: Botulinum toxin type A induced a reduction in pain, indicating that this might be an innovative, less invasive treatment in patients affected by severe hip osteoarthritis, with remarkable effects on the clinical management of this disease.

Lay Abstract


Do you want to comment on this paper? The comments will show up here and if appropriate the comments will also separately be forwarded to the authors. You need to login/create an account to comment on articles. Click here to login/create an account.